Delhi court rejects Bayer injunction
against Natco Pharma generic
India’s Delhi High Court has dismissed a petition for an
injunction by German pharma company Bayer against an Indian competitor. In a
judgment on Thursday July 11, the court said Bayer could not stop Natco Pharma
from launching a generic used to treat colorectal cancer and advanced
gastrointestinal tumours. The dismissal comes after an earlier July 5 ruling in
which Bayer secured an injunction against Natco, but Natco appealed the
decision….
Inequitable Conduct Accusations Still
Powerful Pharma Patent Litigation Tool Post-Therasense
When proven, accusations of fraud-like behavior in the
Patent Office make patents unenforceable, but the Federal Circuit has called
such accusations a “plague” on the system. Cooley’s Jason A. Lief takes a look
at the law of inequitable conduct after the Federal Circuit’s Therasense
opinion. Accusations are the currency of conflict. True accusations reveal
wrongdoing; false accusations harm reputations, subject the accused to ordeal
and waste resources….
Merck & Co., Mylan Settle Patent Suit
on Noxafil Antifungal Copy
Merck and Mylan have settled a lawsuit in which Merck had
accused Mylan’s proposed generic of the antifungal Noxafil of infringing two patents
for the injectable version of the drug.
• Mylan is
blocked from making copies “unless otherwise specifically authorized pursuant
to the settlement,” according to agreement approved Monday in federal court in
Wilmington, Delaware
• Patents
expire in June and July 2031, according to filing
• Merck
previously had reached settlements with Actavis, Roxane, Par and Fresenius,
allowing each to launch...
The revised Rules of Procedure of the
EPO Boards of Appeal
The Boards of Appeal of the European Patent Office (EPO)
published on 3 July 2019 their revised Rules of Procedure, which will come into
force on 1 January 2020 and will apply also to pending appeals (with some
exceptions under Article 25, see below). The revision includes several changes,
in particular the introduction of a so-called “convergent approach”, which
comprises the following three levels…
Endo Pharma To Pay $2.3M To 18 States In Lidoderm Deal
Endo Pharmaceuticals Inc. has agreed to pay $2.3 million to 18 states in a deal ... The states, including Illinois, Florida, Hawaii and Utah, claim Endo had an ... joint motion for a settlement agreement and stipulated order also filed Friday. ... due to concerns over drug prices and repeated antitrust allegations....
No comments:
Post a Comment